Table 3.

Multivariate analysis for CS at diagnosis and 1, 2, 3, and 5 years from diagnosis.

Variable	Survival from diagnosis	CS – year 1	CS – year 2	CS – year 3	CS – year 5
	HR0 (95%CI)	HR1 (95%CI)	HR2 (95%CI)	HR3 (95%CI)	HR5 (95%CI)
Age ≥ 65 years	1.60 (1.3–1.97)	1.57 (1.26–1.96)	1.55 (1.21–2.00)	1.48 (1.11–1.96)	1.95 (1.34–2.82)
Calcium ≥ 11 mg/dL	1.59 (1.17–2.16)	1.63 (1.16–2.29)	1.16 (0.73–1.85)	1.05 (0.59–1.86)	1.05 (0.46–2.41)
ISS III (vs I/II)	1.74 (1.42–2.14)	1.75 (1.4–2.19)	1.76 (1.36–2.28)	1.80 (1.34–2.41)	1.52 (0.99–2.32)
Early SCT	0.57 (0.46–0.70)	0.64 (0.51–0.80)	0.65 (0.50–0.83)	0.61 (0.46–0.81)	0.69 (0.48–1.00)
PI + IMiD induction	0.59 (0.46–0.76)	0.63 (0.48–0.82)	0.67 (0.48–0.92)	0.66 (0.45–0.98)	0.53 (0.29–0.98)
High LDH	1.29 (1.00–1.66)	1.15 (0.86–1.52)	0.96 (0.67–1.38)	1.13 (0.76–1.68)	0.89 (0.48–1.63)
Ch17 Abn	1.53 (1.19–1.98)	1.43 (1.07–1.90)	1.3 (0.92–1.82)	1.32 (0.89–1.95)	1.16 (0.64–2.09)
High-risk IgH trans	1.90 (1.48–2.45)	1.97 (1.49–2.61)	1.81 (1.29–2.55)	1.55 (1.03–2.34)	1.51 (0.80–2.85)
Monosomy 13	1.13 (0.92–1.37)	1.09 (0.88–1.36)	1.05 (0.82–1.34)	1.05 (0.79–1.39)	0.86 (0.59–1.25)
1q gain	1.34 (1.08–1.67)	1.31 (1.04–1.66)	1.51 (1.16–1.97)	1.50 (1.1–2.05)	1.38 (0.89–2.13)

HR Hazard ratio, CS Conditional survival, CI Confidence interval, ISS international staging system, R-ISS Revised international staging system, SCT Stem cell transplant, PI proteasome inhibitor, IMiD Immunomodulatory drug, LDH Lactate dehydrogenase, Abn Abnormality, trans Translocation, Ch17 Chromosome 17.